

About OMICS Group

OMICS Group is an amalgamation of [Open Access Publications](#) and worldwide international science conferences and events. Established in the year 2007 with the sole aim of making the information on Sciences and technology 'Open Access', OMICS Group publishes 500 online open access [scholarly journals](#) in all aspects of Science, Engineering, Management and Technology journals. OMICS Group has been instrumental in taking the knowledge on Science & technology to the doorsteps of ordinary men and women. Research Scholars, Students, Libraries, Educational Institutions, Research centers and the industry are main stakeholders that benefitted greatly from this knowledge dissemination. OMICS Group also organizes 500 [International conferences](#) annually across the globe, where knowledge transfer takes place through debates, round table discussions, poster presentations, workshops, symposia and exhibitions.

OMICS International is a pioneer and leading science event organizer, which publishes around 500 open access journals and conducts over 500 Medical, Clinical, Engineering, Life Sciences, Pharma scientific conferences all over the globe annually with the support of more than 1000 scientific associations and 30,000 editorial board members and 3.5 million followers to its credit.

OMICS Group has organized 500 conferences, workshops and national symposiums across the major cities including San Francisco, Las Vegas, San Antonio, Omaha, Orlando, Raleigh, Santa Clara, Chicago, Philadelphia, Baltimore, United Kingdom, Valencia, Dubai, Beijing, Hyderabad, Bengaluru and Mumbai.

Mexico and Brazil: Lands for bioequivalence testing and generic product registration IFaB as a choice for your trials

6th World Congress on Bioavailability & Bioequivalence: BA/BE Studies Summit
Aug 17-19, 2015 Chicago, USA



Dr. Marlene Llópez
CEO

- Who are we
 - Our Vision
 - Our Mission
 - Our Purpose
 - Our Goals
 - Management Overview
 - Our Business
 - Initiatives
 - CEO's Message
-



Who Are We

Who We Are

IFaB comprises of a team of highly qualified and renowned professionals with various areas of expertise related to medicines.

The team has over ten years of wide-range experience working together while also offering a distinctive approach to clinical pharmacology and bio-pharmacy.

IFaB is an organization dedicated to providing research, training and technical-scientific support to the pharmaceutical industry, both domestically and internationally.

We provide top-quality services for the development of new drugs from both the biopharmaceutical, as well as the clinical pharmacology perspective.





Our Vision

To consolidate IFaB - even further - as a professional research and development organization, with a global presence and strong commitment to its partners, employees, customers and stakeholders.





Our Mission

To provide professional scientific and technological services to the pharmaceutical industry.

Our ***objective*** is to encourage the development of highly-effective and safe drugs of demonstrated quality, achieved through the use of highly specialized, technological and human infrastructure that meets international technical, scientific, regulatory and ethical standards.

Our ***mission*** is to protect the public against health risks produced by the use and consumption of health products and the occurrence of emergencies through the regulation, control and prevention of health risks.

The well-being of our volunteers is ***our first priority*** and the foundation to our mission and ethical commitment.



Our Purpose



To respond to the needs and requirements for research and development of new drugs, as well as the validation processes of generics and new combinations.



To respond to the harmonization and regulatory processes being implemented worldwide.



To contribute to the development of bio pharmaceuticals and clinical pharmacology locally, regionally and globally.



Our Goals

1

To become the first choice and preferred partner in early phase clinical pharmacology units and bio pharmaceutical companies on both a national and global level

2

To continuously train our competitive human resources to serve our clients in a timely and efficient manner



3

To continuously enhance our facilities to improve efficiency and provide our clients with accurate results



Management Overview

A Highly Experienced Management Team



Marlene Llópiz, BA, MD, MPH - CEO

Dr. Llópiz holds a degree in biochemistry from Austin College, an MD degree from the Universidad Anahuac and a Master in Public Health degree from the Harvard University School of Public Health. She was president of the Association of Medical Specialists in the Pharmaceutical Industry, is a honorary member of the CPhI Advisory Board, Secretary General of IFAPP, etc. She has received several national and international honor awards and is currently, a finalist for the Lifetime Achievement Award for Eye for Pharma. She has written several articles and books on clinical research and pharmaceutical medicine. She has over 20 years experience in contract research organizations including being Country Manager at Quintiles, ICON and Venn Life Sciences. She hold ACRP and RAPS certificates.


Federico Arguelles, MD, MS – Clinical Operations Director

Dr. Arguelles is the Ex-Commissioner for the National Regulatory Agency in Mexico (COFEPRIS). He is a highly experienced physician in regulatory affairs, clinical operations and international strategies for all types of trials in both Mexico and abroad.

Luis Garcia - Analytical Area Director

Mr. Garcia holds a Masters Degree in Biopharmacy. He has wide experience in the development and validation of bio-analytical methods, as well as in pharmacokinetics and biostatistics. He is a member of several national and international scientific societies.

IFaB / 71 employees




Management

NAME	ROLE	
MARLENE LLOPIZ	CEO	Master Degree in Public Health, Medical Doctor, Bachelor of Science in Biochemistry
LUIS GARCIA	ANALYTICAL DIRECTOR	Master Degree in Pharmacy
ISABEL RUIZ	ANALYTICAL SUBDIRECTOR	PhD PK/PD
CLAUDIA LARA	BIOSTATISTICIAN	Master Degree in Health Sciences
LIZ MEDINA	PHARMACOKINETICS SPECIALIST A	Master Degree in Pharmacy
JAIME PONCE	BUSINESS DEVELOPMENT	MBA



Our Business

IFaB is a Complete Provider of Clinical Services



Our Business



At A Glance



~15%¹
Market
Share

Over 70
Employees



2
Certifications

Analytical +
Clinical + QA
Areas




40 Studies in
Pipeline



70 Studies in
Backlog

¹ Representative of the total number of projects from 3Q14 to 1Q15



Sponsors	Special needs – Best practices knowledge are incorporated in SOP's
Local Pharma	<ul style="list-style-type: none"> • Scientific and Regulatory Consulting Services • Global Expansion Strategies • Aggressive timelines • SOPs, Global Communication, • Global Quality Standards • Homologated Analytic Methods, Follow up across the Complete Process
Regional / Global	
CRO's	
Gx Corps	

Clinical Pharmacology Services


- Bioequivalence
- Bioavailability
- Concept Trials
- Phase I
- Early Phase II
- Pharmacovigilance
- Pharmacoeconomics
- Pharmacokinetic Studies



- Bio-statistical analysis
- Dissolution profiles to test for interchangeability and for bio-waivers
- Development, validation and application of bio-analytical methods for the quantification of drugs, biomarkers and biotechnology drugs in biological matrixes



Experience



> 300
Studies

Over 20,000
volunteers



Over 8 Phase
II studies



More than
13 Phase I
studies



> 110
Bioequivalence
studies

> 20
Bioavailability
studies



158 Validated Methods



1	Metamizol	31	Carvedilol	61	Fluconazol	91	Loratadina	121	Pentoxifilina	151	Sulfametoxazol
2	Acetaminofen	32	Cefaclor	62	Fluoxetina	92	Losartán	122	Pioglitazona	152	Trimetoxibenceno
3	Aciclovir	33	Cefadroxil	63	Fluoxetina	93	Mebeverina	123	Piroxicam	153	Valsartán
4	Valaciclovir	34	Cefalexina	64	Flutamida	94	Meloxicam	124	Pramipexol	154	Venlafaxina
5	Ácido acetil salicílico	35	Cefalona	65	Furosemida	95	Memantina	125	Pravastatina	155	Voriconazol
6	Ácido clávulónico	36	Cefuroxima	66	Gabapentina	96	Metformina	126	Prednisolona	156	Zalcitabina
7	Ácido Fólico	37	Ciprofloxacino	67	Gatifloxacina	97	Metamizol	127	Pregabalina	157	Zidovudina
8	Ácido Micofenólico	38	Cisaprida	68	Glibenclamida	98	Metilprednisolona	128	Progesterona	158	Zolpidem
9	Ácido Valpróico	39	Citalopram	69	Glimepirida	99	Metoprolol	129	Quetiapina		
10	Albendazol	40	Clindamicina	70	Glucosamina	100	Metotrexato	130	Ranitidina		
11	Alopurinol	41	Clonazepam	71	Hidroclorotiazida	101	Metronidazol	131	Rifampicina		
12	Alprazolam	42	Clopidogrel	72	Hidroxicloroquina	102	Mirtazapina	132	Risperidona		
13	Amlodipino	43	Clormadinona	73	Ibandronato	103	Moclobemida	133	Rosuvastatina		
14	Amoxicilina	44	Clortalidona	74	Ibuprofeno	104	Montelukast	134	Sertralina		
15	ácido Clavulánico	45	Deflazacort	75	Imipramina	105	Naproxeno	135	Sildenafil		
16	Ampicilina	46	Dextrometorfano	76	Indometacina	106	Carisoprodol	136	Simvastatina		
17	Anastrozol	47	Diacereina	77	Irbesartán	107	Nebivolol	137	Sirolimus		
18	Atenolol	48	Diclofenaco	78	Isoniazida	108	Nimesulida	138	Stavudina		
19	Atomoxetina	49	Dicloxacilina	79	Ketoconazol	109	Nimodipino	139	Tacrolimus		
20	Azitromicina	50	Donepezilo	80	Ketorolaco	110	Norfloxacino	140	Talidomida		
21	Betahistina	51	Doxiciclina	81	Lacosamida	111	Ofloxacina	141	Tamoxifeno		
22	Bicalutamida	52	Duloxetina	82	Lamivudina	112	Olanzapina	142	Tamsulosina		
23	Biperidina	53	Eltrombopag	83	Lamotrigina	113	Olmesartan	143	Telmisartán		
24	Bromazepam	54	Enalapril	84	Lansoprazol	114	Omeprazol	144	Terazosina		
25	Bromhexina	55	Escitalopram	85	Letrozol	115	Oxibutinina	145	Terbinafina		
26	Cabergolina	56	Exemestano	86	Levetiracetam	116	Oxitetraciclina	146	Tiocolchicosida		
27	Candesartán	57	Fenazopiridina	87	Levocetirizina	117	Pantoprazol	147	Topiramato		
28	Captopril	58	Fenitoina	88	Levofloxacino	118	Paroxetina	148	Tramadol		
29	Carbamazepina	59	Finasterida	89	Levonorgestrel	119	Paroxetina	149	Trimebutina		
30	Carisoprodol	60	Floroglucinol	90	Lisinopril	120	Penicilina	150	Trimetoprima		

Facilities


- **Clinical Area:** One of the largest clinical areas in the country, with over 80 beds, medical offices, a phlebotomy area and medical contingency zones.

It also has diagnostic and emergency equipment, including defibrillators, transfer equipment and monitors.

- **Analytical Area:** Equipped with state-of-the-art technology enabling the company to perform highly complex studies. There are also sample extraction, reception and storage areas.
- **Quality Control Area:** There is an independent area where quality management takes place ensuring that the highest standards are consistently achieved and any arising risks are properly managed.



Opportunities





- Certified by COFEPRIS, the Mexican Health Authority.



- Certified by ANVISA, the Brazilian Health Authority.
- IFaB is the only non-Brazilian company in America that has an ANVISA certification for clinical, analytical studies and statistics.



Initiatives

Social initiatives: Generic equivalents of brand-name drugs allow lower income individuals to have access to treatment that can save or improve the quality of their lives.



IFaB is delivering to society by reassuring the quality of generics that become accessible to people at the bottom end of the socio-economic ladder.

Environmental initiatives: The company has also taken distinct steps toward monitoring its environmental impact by hiring an expert in the topic.





CEO's Message

IFaB has grown tremendously over the last decade and will continue to do so over the next few years.

Much of our success has been and is attributed to our team's experience, commitment and desire to positively contribute towards our society, clients, and stakeholders by **upholding the highest standards in the pharmaceutical industry.**

Going forward, the delivery on our promises, goals and visions will continue to play an instrumental role in achieving further success so that together we can continue on the road to achieving sustainable and continued growth.



MARLENE LLOPIZ
CHIEF EXECUTIVE OFFICER



Thank you

Let us meet again..

We welcome you all to our future conferences of
OMICS International
**7th World Congress on
Bioavailability & Bioequivalence: BA/BE Studies Summit**
On
August 29 - 31, 2016 at Atlanta, USA

[http://bioavailability-
bioequivalence.pharmaceuticalconferences.com/](http://bioavailability-bioequivalence.pharmaceuticalconferences.com/)